Magainin Pharmaceuticals, Inc.

Magainin Pharmaaceuticals Inc.

Inkine Pharmaceutical, Inc.

Leonard S Jacob

W Lee Maloy

Taffy J Williams

Barry Berkowitz

Margaret A Baker

Robert D Krell

Orally administered colonic purgative formulations and methods of its use for effecting partial or complete purgation of the colon in mammals, the formulations consisting of non-aqueous admixtures of a purgative salt selected from the group consisting of Mg.sub.3 (PO.sub.4).sub.2, MgHPO.sub.4, Mg(H.sub.2 PO.sub.4).sub.2, MgSO.sub.4, MgCl.sub.2, Na.sub.2 SO.sub.4, sodium tartrate, potassium tartrate, magnesium tartrate and mixtures, thereof, administered in tablet or capsule form in purgative effective concentrations. Preferred embodiments make use of at least one or more magnesium phosphate salts, more preferably dibasic magnesium phosphate; other preferred embodiments include the addition of binders, dispersants and buffers which do not adversely affect osmolality or effectiveness of the purgative formulations.

Non-aqueous colonic purgative formulations

A process for treating a gynecological malignancy in a host which comprises administering to the host at least one biologically active amphiphilic peptide or protein. The peptide or protein may be administered intralesionally, intravenously, or intraperitoneally, whereby the peptide or protein may inhibit, prevent, or destroy the growth of the gynecological malignancy, such as an ovarian cancer, uterine cancer, or cervical cancer.

Treatment of gynecological malignancies with biologically active peptides

A composition comprising a biologically active amphiphilic ion channel-forming peptide or ion channel forming protein and a toxic cation, such as a silver cation. Such compositions may be employed as pharmaceuticals, particularly for the treatment and prevention of eye infections.

Composition and treatment with biologically active peptides and toxic

Growing community of inventors

Penn Valley, PA, United States of America

Leonard S Jacob